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NomogramInflammatory markers have been proposed to predict clinical outcomes in many types of cancers.
The purpose of this study was to explore the influence of the lymphocyte-to-monocyte ratio
(LMR) on clinical prognosis of patients with osteosarcoma. This study collected 327 patients who
underwent surgical treatment for osteosarcoma during the period 2006–2010. LMR was calculated
from pre-operative peripheral blood cells counts. The optimal cut-off value of LMR was determined
based on receiver operating characteristic curve analysis. Overall survival (OS) and event free sur-
vival (EFS) was plotted using the Kaplan–Meier method and evaluated by the log-rank test. A predic-
tive model was established to predict clinical prognosis for OS, and the predictive accuracy of this
model was determined by concordance index (c-index). Our results showed that young age, elevated
alkaline phosphatase, metastasis at diagnosis, chemotherapy, lymphocyte and monocyte counts
were significantly associated with LMR. Low LMR was associated with shorter OS and EFS
(P < 0.001), and was an independent predictor of both OS and EFS (HR = 1.72, 95% CI = 1.14–2.60,
P = 0.010; HR = 1.89, 95% CI = 1.32–2.57, P = 0.009). The nomogram performed well in the prediction
of overall survival in patients with osteosarcoma (c-index 0.630). In conclusion, low pre-operative
LMR is associated with a poor prognosis in patients suffering from osteosarcoma. A prospective
study is warranted for further validation of our results.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction decades, the overall 5-year survival remains unsatisfactory forOsteosarcoma is the most common primary malignant tumors
of bone [1]. Epidemiological data showed that there were two
peaks of incidence in osteosarcoma patients, particularly among
early adolescence aged 15–19 years [2]. In recent years, patients’
age with osteosarcoma is increasing [3] and patients over the age
of 40 years account for 13–30% of all patients with osteosarcoma
[4]. According to epidemiological data, osteosarcoma is the eighth
leading cancer with an incidence of 4.4 per million, mainly occur-
ring in adolescents and adults [5]. Despite substantial progress
achieved in diagnosis and treatment for osteosarcoma in the pastlocal relapse or metastasis after surgical resection of primary
osteosarcoma.
The poor clinical prognosis of osteosarcoma partially results
from lack of a good indicator to detect tumors at an early stage.
Furthermore, the ability to predict the prognosis of a patient is
indispensable for selecting the optimal treatment plan and
follow-up strategies. Although prognostic indicators are the
Enneking surgical criteria [6] and alkaline phosphatase, heteroge-
neous clinical outcomes are frequently found within the same
tumor stage. Therefore, it is necessary for us to further understand
the underlying mechanisms and find a dependable indicator of
osteosarcoma to predict clinical outcome.
Recently, the emerging evidence revealed that the systemic
inflammatory response has been reported to be an independent
prognostic biomarker in various types of tumor [7,8]. Published
evidence has shown a significant link between inflammatory mark-
ers and poor prognosis in several types of tumors, including throm-
bocytosis, leukocytosis, high neutrophil-to-lymphocyte ratio (NLR)
or platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-
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the prognosis of osteosarcoma patient has been not reported.
Herein, the purpose of this study was to estimate the influence of
LMR on clinical prognosis in 327 osteosarcoma patients at post-
operation.
2. Materials and methods
2.1. Patients
The Medical Ethics Committee of The First People’s Hospital of
Anqing approved this study. Written informed consents were
obtained from all eligible patients. Medical records of all newly
diagnosed osteosarcoma patients between 2006 and 2010 in The
First People’s Hospital of Anqing and The Second People’s
Hospital of Lianyungong were reviewed and retrospectively ana-
lyzed in the present study. The diagnosis of osteosarcoma was con-
firmed depended on histological evidence and classified on the
basis of the Enneking surgical criteria [6]. The inclusion criteria
were as follows: (1) no prior pre-operative anticancer treatment,
such as chemotherapy, blood transfusion, and radiotherapy. (2)
All patients with osteosarcoma underwent surgical resection. (3)
No hematology disease, infection and hyperpyrexia. (4) Informed
consents were obtained. Finally, 327 patients were enrolled in
the present study. Clinical features of eligible patients were col-
lected including age, sex, tumor location, pathological fracture,
alkaline phosphatase (ALP), clinical stage, metastasis at diagnosis
and post-operative chemotherapy.
2.2. Blood sample analysis
Blood samples were obtained for the measurement of lympho-
cyte and monocyte counts at pre-operation.
2.3. Definition and optimal cut-off value of LMR
LMR was defined as the lymphocyte counts divided by the
monocyte counts. Using overall survival (OS), as end-point, the
optimal cut-off value of LMR was obtained when the Youden index
was maximal. Subsequently, patients with a LMR greater than the
corresponding cut-off value were defined as high LMR (HLMR), and
others were defined as low LMR (LLMR).
2.4. Patient follow-up
Each patient was followed up regularly until death or December
2014 at post-operation. Physical examination, laboratory tests and
imageological diagnosis were performed at every visit. The follow-
up period varied from 3 months to 5 years, with a median of
24 months. OS was calculated from the data of surgical resection
to the data of death. Event free survival (EFS) was calculated from
the data of surgical resection to the data of disease relapse, pro-
gression or tumor-related death. The date of last follow-up was
used for drop-out patients.
2.5. Statistical analysis
To evaluate the sensitivity and specificity of the 5-year OS, the
receiver operating characteristic (ROC) curve was applied and
Youden index was estimated to determine the optimal LMR cut-
off value. Comparison of categorical variables was conducted using
a Chi-square test. Comparison of continuous variables was con-
ducted using a Student’s t test. Survival curves were plotted by
the Kaplan–Meier method and the significance was assessed bythe log-rank test. Significant predictors for OS and EFS determined
by univariate analysis were evaluated by multivariate analysis
using Cox’s proportional hazards model. Nomogram for OS was
performed by R 3.0.3 software using the package of rms (Institute
for Statistics and Mathematics, Austria). A final model selection
was performed by a backward step-down selection process, and
Harrell’s concordance index (c-index) was applied to evaluate the
predictive accuracy. All results analyses were conducted by SPSS
17.0 software (IBM, USA). P values less than 0.05 were considered
statistically significant.
3. Result
3.1. Clinicopathologic characteristics
Of 327 patients with osteosarcoma, 235 (71.9%) were male, and
the mean age was 20 years (range 10–44 years; Table 1). The medi-
ans of lymphocyte counts and monocyte counts were 1220 and
340 per lL, respectively. 130 (39.8%) patients with initial metasta-
sis and 58 (17.7%) patients with pathological fracture were
recorded from newly diagnosed patients. According to Enneking
surgical staging criteria, the number of stage I–II and III was 168
(51.4%) and 159 (48.6%), respectively. Pathological results sug-
gested that 267 (81.7%) patients’ osteosarcomas were located in
the tibia or femur. During the follow-up period, 166 (50.8%)
patients had experienced systemic chemotherapy. Among all
enrolled patients, 184 (56.3%) patients died from cancer-related
disease, and 217 (66.4%) patients experienced disease relapse, pro-
gression or tumor-related death.
3.2. The optimal cut-off value for LMR
The areas under the curve (AUC) for LMR were 0.665 (P < 0.001,
Fig. 1), when the OS was employed as end-point for LMR. The opti-
mal cut-off value was 3.43 for LMR. All patients were divided into
two groups with the high group that P the cut-off value (HLMR)
and the low group less than the cut-off value (LLMR) on the basis
of the optimal cut-off value.
3.3. The associations of LMR with clinicopathologic features
To explore associations of LMR with clinicopathologic features
of osteosarcoma patients, comparisons between the high and low
groups for LMR were carried out (Table 1). Our results indicated
that young age, elevated ALP, metastasis at diagnosis, chemother-
apy, lymphocyte counts and monocyte counts were significantly
associated with LMR (P < 0.05). However, patients’ sex, tumor loca-
tion, pathological fracture and clinical stage were not found to be
associated with LMR.
3.4. Prognostic factors for OS and EFS
The Kaplan–Meier curve showed that the 5-year OS rates of the
LLMR group were significantly lower than those of the HLMR group
(P < 0.001; Fig. 2A), and similar result was also observed in the 5-
year EFS rates (P < 0.001; Fig. 2B). Subsequently, univariate analy-
ses indicated that advanced clinical stage, metastasis at diagnosis,
chemotherapy and LLMR were closely correlated with poor prog-
nosis. Furthermore, multivariate analyses of OS and EFS were per-
formed including age, sex and clinical variables with univariate
log-rank P < 0.05: advanced clinical stage, metastasis at diagnosis,
chemotherapy and LLMR. LLMR, advanced clinical stage and
metastasis emerged as markers for shorter OS and EFS (Table 2),
Table 1
Association of the patients’ clinical parameters with LMR.
Clinical
parameters
Total N = 327 (%) LMR P
LLMR n = 194 (%) HLMR n = 133 (%)
Age (year)
520 217 (66.4%) 144 (74.2%) 73 (54.9%) 0.000
>20 110 (33.6%) 50 (25.8%) 60 (45.1%)
Sex
Male 235 (71.9%) 145 (44.3%) 90 (67.7%) 0.162
Female 92 (28.1%) 49 (55.7%) 43 (33.3%)
Tumor location
Tibia/
femur
267 (81.7%) 152 (78.4%) 115 (86.5%) 0.063
Elsewhere 60 (18.3%) 42 (21.6%) 18 (13.5%)
Pathological fracture
Yes 58 (17.7%) 32 (16.5%) 26 (19.5%) 0.478
No 269 (82.3%) 162 (83.5%) 107 (80.5%)
ALP
Elevated 147 (45.0%) 97 (50.0%) 50 (37.6%) 0.027
Normal 180 (55.0%) 97 (50.0%) 83 (62.4%)
Clinical stagea
I–II 168 (51.4%) 92 (47.4%) 76 (57.1%) 0.084
III 159 (48.6%) 102 (52.6%) 57 (42.9%)
Metastasis at diagnosis
Present 130 (39.8%) 98 (50.5%) 32 (24.1%) 0.000
Absent 197 (60.2%) 96 (49.5%) 101 (75.9%)
Chemotherapy
Yes 166 (50.8%) 77 (39.7%) 89 (66.9%) 0.000
No 161 (49.2%) 117 (60.3%) 44 (33.1%)
Lymphocyte
counts
(103/lL)b
1.22 (0.08–4.85) 1.57 (0.60–4.83) 0.91 (0.09–4.44) 0.000
Monocyte
counts
(103/lL)b
0.34 (0.02–1.76) 0.34 (0.02–1.76) 0.31 (0.03–0.88) 0.000
ALP, alkaline phosphatase; LMR, lymphocyte-to-monocyte ratio; HLMR, high LMR;
LLMR, low LMR.
a Clinical stage according to Enneking surgical stage.
b Median (range).
Fig. 1. ROC curves for LMR. The optimal cut-off level of LMR was determined based
on the largest of sensitivity and specificity by receiver operating characteristic
curve (ROC) analysis for overall survival.
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patients with osteosarcoma.
3.5. Prognostic nomogram for OS
To further predict the overall survival of osteosarcoma patients
after surgical resection, a predictive model was constructed by Cox
regression model analysis using all the significant independent risk
factors for OS (Fig. 3). It can predict the probability of death of
osteosarcoma within 3 or 5 years after operation, assuming the
patient does not die of another cause first. The c-index for OS pre-
diction was 0.630.Fig. 2. Kaplan–Meier curves for survival probability according to LMR levels. (A)
Patients with LMR 6 3.43 had a significantly associated with worse overall survival
than those with LMR > 3.43; (B) patients with LMR 6 3.43 had a significantly
associated with worse event free survival than those with LMR > 3.43.
Table 2
Univariate and multivariate analyses of clinical parameters for the prediction of overall survival and event free survival.
Clinical parameters Overall survival Event free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) P Adjusted HR (95% CI) P HR (95% CI) P Adjusted HR (95% CI) P
Age (year)
520 1 1 1 1
>20 0.82 (0.60–1.12) 0.211 0.85 (0.62–1.16) 0.309 0.87 (0.66–1.15) 0.328 0.92 (0.69–1.23) 0.575
Sex
Male 1 1 1 1
Female 0.85 (0.61–1.18) 0.336 1.00 (0.71–1.40) 0.991 0.92 (0.68–1.24) 0.586 0.94 (0.69–1.27) 0.666
Tumor location
Tibia/femur 1 1
Elsewhere 0.83 (0.58–1.19) 0.313 0.77 (0.55–1.07) 0.113
Pathological fracture
Yes 1 1
No 0.95 (0.65–1.37) 0.765 0.94 (0.66–1.32) 0.706
ALP
Normal 1 1
Elevated 1.04 (0.77–1.39) 0.810 1.01 (0.78–1.32) 0.925
Clinical stagea
I–II 1 1 1 1
III 1.59 (1.19–2.12) 0.002 1.44 (1.08–1.93) 0.015 1.46 (1.08–1.83) 0.013 1.21 (1.01–1.59) 0.027
Metastasis at diagnosis
Absent 1 1 1 1
Present 3.75 (2.76–5.10) 0.000 2.56 (1.73–3.80) 0.000 3.87 (3.17–4.79) 0.000 2.90 (2.31–3.75) 0.001
Chemotherapy
Yes 1 1 1 1
No 1.95 (1.45–2.61) 0.000 1.27 (0.93–1.74) 0.140 2.73 (2.32–3.27) 0.000 1.32 (1.00–1.76) 0.054
LMR
HLMR 1 1 1 1
LLMR 2.97 (2.16–4.08) 0.000 1.72 (1.14–2.60) 0.010 3.49 (2.86–4.32) 0.000 1.89 (1.32–2.57) 0.009
ALP, alkaline phosphatase; LMR, lymphocyte -to-monocyte ratio; HLMR, high LMR; LLMR, low LMR; HR, hazard ratio; CI, confidence interval.
Statistically significant results were in bold.
a Clinical stage according to Enneking surgical stage.
Fig. 3. Postoperative nomogram with LMR and significant clinicopathologic characteristics predicted the probability of osteosarcoma for overall survival. To use it, an
individual patient’s value is located on each variable axis, and a line is drawn upward to determine the number of points received for each variable parameter. The sum of
these points is located on the Total Points axis, and a line is drawn downward to the survival axes to determine the probability of 3- or 5-year survival.
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We investigated the influence of LMR on clinical prognosis of
patients with osteosarcoma which has reflected a systemic inflam-
matory response. The pre-operative LLMR in the peripheral blood of
osteosarcoma patients was significantly associated with poor prog-
nosis following surgery. Despite advanced progress in theunderstanding of the association between inflammatory biomark-
ers and prognosis of various cancers [7,14–16], the impact of
inflammatory markers on clinical prognosis of osteosarcoma
patients remains confused. Herein, this current study was the first
attempt to evaluate the prognosis of patients with osteosarcoma
based on LMR in the peripheral blood and establish a predictive
model to improve the predictive accuracy. As the peripheral blood
686 T. Liu et al. / FEBS Open Bio 5 (2015) 682–687cell counts test is routinely performed without need for additional
effort in all patients with cancer, it is a simple, reproducible, and
inexpensive parameter of the inflammatory response as well as a
prognostic biomarker. Interestingly, LMR could be considered as
an independent indicator for both OS and EFS by multivariate
analyses.
Rudolf Virchow et al. first showed that ‘‘lymphoreticular infil-
trate” could reflect the origin of tumor at the sites of chronic
inflammation [17]. Over the past decades, Virchow’s hypothesis
was proved by the emerging studies, revealing the impact of
inflammatory microenvironment on tumor. The inflammatory
response, which is implicated in repair of tissue damage due to
tumors, is an indispensable factor in the tumor cell microenviron-
ment [18,19]. Hence, inflammatory cells participate in tumor pro-
liferation, invasion, migration, angiogenesis and metastasis.
Meanwhile, tumors could result from inflammatory sites, possibly
by the recruitment of inflammatory cells, chemokines and cyto-
kines. Therefore, the adaptive immune system may be converted,
and this inflammatory response reactivates tumor development
and progression. The inflammatory response could cause leukocy-
tosis and lymphocytopenia [20]. The lymphocyte response plays a
critical role in the suppression of tumor progression [21]. The pos-
sible mechanisms underlying neutrophilia in tumor progression
and metastasis are the release of reactive oxygen species or nitric
oxide and remodeling of the extracellular matrix [22]. Hence, bet-
ter understanding of the links between inflammation and tumor
contributes to the treatment and prevention of tumor. Various
biomarkers have been reported to reflect the association of inflam-
mation and tumor, such as interferon-gamma/interleukin-4 ratio
[23] and inflammation-based prognostic score on the basis of
CRP and albumin levels [24]. The systemic inflammatory marker
(LMR) may be also considered as potential prognostic factors for
various types of tumors. Chen et al. reported that a decreased pre-
treatment LMR is associated with a poor prognosis in cervical can-
cer patients [13]. Jiang et al. used pretreatment LMR as an
independent prognostic factor in patients with metastatic
nasopharyngeal carcinoma [25]. Zhang et al. found that pre-
operative LMR is a better prognostic factor in bladder cancer
patients undergoing radical cystectomy [26].
Little evidence has shown that LMR is associated with progno-
sis in osteosarcoma. Our study was first attempt to evaluate the
influence of LMR on prognosis of 327 osteosarcoma patients
and establish a predictive model to improve the predictive accu-
racy for 3-year and 5-year overall survival. Similar to other
results in various cancers, pre-operative LLMR was significantly
associated with poor prognosis. Interestingly, a decreased pre-
operative LMR could be regarded as an independent prognostic
factor for both OS and EFS in patients with osteosarcoma. Our
constructed nomogram performed well in the prediction of over-
all survival (c-index 0.630). These data supported that the nomo-
gram could better predict prognosis in osteosarcoma patients at
post-operation.
Some limitations of our study should be acknowledged. Firstly,
the study was a retrospective design, with a small population size
of 327 patients, which resulted in no significant association
between clinical prognosis and chemotherapy. Secondly, the
peripheral blood findings were not compared with findings of per-
itumoral inflammation in the primary osteosarcoma tissue.
Nevertheless, data in peripheral blood provided a novel horizon
to understand the role of LMR in the development and progression
of osteosarcoma. Finally, some heterogeneities were appeared in
the treatment of osteosarcoma patients at post-operation, which
resulted in different clinical prognosis. Hence, further prospective
studies are necessary to illuminate the relationship between LMR
and prognosis for patients with osteosarcoma.In summary, the pre-operative LMR is associated with clinical
prognosis of patients with osteosarcoma. Integrate LMR and the
prognostic nomogram may be used to evaluate clinical prognosis
and offer appropriate therapeutic strategy. In future, a prospective
and well-designed study of LMR is warranted for further identifica-
tion of our findings.
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